Clinical Trial Detail

NCT ID NCT02954536
Title Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

esophagus adenocarcinoma

gastric adenocarcinoma

gastroesophageal adenocarcinoma

Therapies

Capecitabine + Cisplatin + Pembrolizumab + Trastuzumab

Age Groups: adult senior

Additional content available in CKB BOOST